Urothelial cancer (UC) is most commonly found in the urinary bladder, but can also appear in the upper urinary tract, where it is associated with several disease-specific challenges affecting its diagnosis, clinical staging, surgical management, and systemic therapy. A significant number of patients experience extra-vesical disease recurrence despite radical nephroureterectomy (RNU), leading to inevitable demise. Over the last years, the therapeutic armamentarium of UC has expanded with several systemic treatment options entering clinical care and deliver the potential to support a more individualized treatment in the near future. Currently, novel targeted therapies are emerging, accompanied with extensive biomarker research, which leads to a better understanding of the disease and therefore, reshaping the treatment landscape continuously and decisively. Though, systemic treatment of UTUC comes along with certain challenges that are specific to the disease, e.g., loss of renal function after RNU, which might result in ineligibility for a cisplatin-based chemotherapy. In this narrative review, the current standard of systemic treatment of UC in the perioperative and metastatic treatment setting are reported, with focus on UTUC. In addition, molecular aspects of UTUC, as well as future directions and specific implications for treatment of patients diagnosed with UTUC are discussed.

Department of Special Surgery University of Jordan Amman Jordan

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology University of Texas Southwestern Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. 10.3322/caac.21590 PubMed DOI

Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017;35:379-87. 10.1007/s00345-016-1928-x PubMed DOI

Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224-33. 10.1002/cncr.24135 PubMed DOI

Favaretto RL, Shariat SF, Savage C, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 2012;109:77-82. 10.1111/j.1464-410X.2011.10288.x PubMed DOI PMC

Janisch F, Shariat SF, Baltzer P, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol 2020;38:1165-75. 10.1007/s00345-019-02875-8 PubMed DOI

Rojas CP, Castle SM, Llanos CA, et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol 2013;31:1696-700. 10.1016/j.urolonc.2012.05.010 PubMed DOI

Freund JE, Duivenvoorden MJC, Sikma BT, et al. The Diagnostic Yield and Concordance of Ureterorenoscopic Biopsies for Grading of Upper Tract Urothelial Carcinoma: A Dutch Nationwide Analysis. J Endourol 2020;34:907-13. 10.1089/end.2020.0246 PubMed DOI

Smith AK, Stephenson AJ, Lane BR, et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011;78:82-6. 10.1016/j.urology.2011.02.038 PubMed DOI

Dev HS, Poo S, Armitage J, et al. Investigating upper urinary tract urothelial carcinomas: a single-centre 10-year experience. World J Urol 2017;35:131-8. 10.1007/s00345-016-1820-8 PubMed DOI PMC

Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol 2021;79:62-79. 10.1016/j.eururo.2020.05.042 PubMed DOI

Chromecki TF, Cha EK, Fajkovic H, et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 2012;61:245-53. 10.1016/j.eururo.2011.09.017 PubMed DOI

Favaretto RL, Shariat SF, Chade DC, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 2010;58:574-80. 10.1016/j.eururo.2010.07.003 PubMed DOI PMC

Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2009;103:307-11. 10.1111/j.1464-410X.2008.08003.x PubMed DOI

Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 2013;49:1889-97. 10.1016/j.ejca.2013.02.001 PubMed DOI

Rink M, Sjoberg D, Comploj E, et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 2012;19:4337-44. 10.1245/s10434-012-2499-8 PubMed DOI PMC

Rouprêt M, Hupertan V, Seisen T, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 2013;189:1662-9. 10.1016/j.juro.2012.10.057 PubMed DOI

Yin M, Joshi M, Meijer RP, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist 2016;21:708-15. 10.1634/theoncologist.2015-0440 PubMed DOI PMC

Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021;79:82-104. 10.1016/j.eururo.2020.03.055 PubMed DOI

Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015;16:76-86. 10.1016/S1470-2045(14)71160-X PubMed DOI

Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020;395:1268-77. 10.1016/S0140-6736(20)30415-3 PubMed DOI PMC

Gust KM, Abufaraj M, D'Andrea D, et al. Second line immune checkpoint inhibition in urothelial cancer. Transl Androl Urol 2019;8:414-20. 10.21037/tau.2019.09.18 PubMed DOI PMC

Hosogoe S, Hatakeyama S, Kusaka A, et al. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. Eur Urol Focus 2018;4:946-53. 10.1016/j.euf.2017.03.013 PubMed DOI

Kubota Y, Hatakeyama S, Tanaka T, et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 2017;8:101500-8. 10.18632/oncotarget.21551 PubMed DOI PMC

Porten S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014;120:1794-9. 10.1002/cncr.28655 PubMed DOI PMC

Kaag MG, O'Malley RL, O'Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010;58:581-7. 10.1016/j.eururo.2010.06.029 PubMed DOI PMC

Kaag M, Trost L, Thompson RH, et al. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int 2014;114:674-9. 10.1111/bju.12597 PubMed DOI

Margulis V, Puligandla M, Trabulsi EJ, et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol 2020;203:690-8. 10.1097/JU.0000000000000644 PubMed DOI PMC

Azizi M, Cheriyan SK, Peyton CC, et al. Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. Curr Treat Options Oncol 2019;20:40. 10.1007/s11864-019-0637-2 PubMed DOI

Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116:3127-34. 10.1002/cncr.25050 PubMed DOI

Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol 2021;79:635-54. 10.1016/j.eururo.2020.07.003 PubMed DOI

Quhal F, Mori K, Sari Motlagh R, et al. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Int J Clin Oncol 2020;25:1037-54. 10.1007/s10147-020-01650-9 PubMed DOI

Foerster B, Abufaraj M, Petros F, et al. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol 2020;203:1101-8. 10.1097/JU.0000000000000737 PubMed DOI

Gust KM, Shariat SF. Re: High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. PractiseUpdate (accessed online May 31st 2019). 2019. PubMed

Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018;36:3353-60. 10.1200/JCO.18.01148 PubMed DOI

Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019;25:1706-14. 10.1038/s41591-019-0628-7 PubMed DOI

Powles T, Rodriguez-Vida A, Duran I, et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). J Clin Oncol 2018;36:abstr 4506.

Necchi A, Briganti A, Raggi D, et al. Interim results from PURE-01: A phase 2, open-label study of neoadjuvant pembrolizumab (pembro) before radical cystectomy for muscle-invasive urothelial bladder carcinoma (MIUC). J Clin Oncol 2018;36:TPS533. 10.1200/JCO.2018.36.6_suppl.TPS533 PubMed DOI

Necchi A, Raggi D, Gust K, et al. PURE-02: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (Pembro), preceding radical nephroureterectomy (RNU), for patients with localized high-risk urothelial carcinoma of the upper urinary tract (UTUC). European Urology Supplements 2019;18:e1835. 10.1016/S1569-9056(19)31329-6 DOI

Gust KM, Shariat SF. Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. Eur Urol 2019;75:695-6. 10.1016/j.eururo.2018.12.034 PubMed DOI

Seisen T, Krasnow RE, Bellmunt J, et al. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol 2017;35:852-60. 10.1200/JCO.2016.69.4141 PubMed DOI

Luo Y, Feng BF, Wei DC, et al. Prospective controlled observation ofeffect of adjuvant chemotherapy onsurvival and prognosis ofhigh-risk upper tract urothelial carcinoma patients underwent radical nephroureterectomy. Zhonghua Yi Xue Za Zhi 2019;99:3158-63. PubMed

Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:525-37. 10.1016/S1470-2045(21)00004-8 PubMed DOI PMC

Powles T, Assaf ZJ, Davarpanah N, et al. 1O - Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy. Ann Oncol 2020;31:S1417-S24. 10.1016/j.annonc.2020.10.486 DOI

Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021;384:2102-14. 10.1056/NEJMoa2034442 PubMed DOI PMC

Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-46. 10.1200/JCO.2001.19.10.2638 PubMed DOI

von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8. 10.1200/JCO.2005.07.757 PubMed DOI

Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;395:1547-57. 10.1016/S0140-6736(20)30230-0 PubMed DOI

Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:931-45. 10.1016/S1470-2045(21)00152-2 PubMed DOI

Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2020;21:1574-88. 10.1016/S1470-2045(20)30541-6 PubMed DOI

Moschini M, Shariat SF, Rouprêt M, et al. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. J Urol 2018;199:1149-57. 10.1016/j.juro.2017.11.068 PubMed DOI

Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2020;383:1218-30. 10.1056/NEJMoa2002788 PubMed DOI

Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013;24:1466-72. 10.1093/annonc/mdt007 PubMed DOI

Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67-76. 10.1016/S0140-6736(16)32455-2 PubMed DOI PMC

Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483-92. 10.1016/S1470-2045(17)30616-2 PubMed DOI

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015-26. 10.1056/NEJMoa1613683 PubMed DOI PMC

Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748-57. 10.1016/S0140-6736(17)33297-X PubMed DOI

Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312-22. 10.1016/S1470-2045(17)30065-7 PubMed DOI

Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol 2017;3:e172411. 10.1001/jamaoncol.2017.2411 PubMed DOI PMC

Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol 2017;35:2117-24. 10.1200/JCO.2016.71.6795 PubMed DOI PMC

Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 2019;10:2977. 10.1038/s41467-019-10873-y PubMed DOI PMC

Mollica V, Rizzo A, Montironi R, et al. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers (Basel) 2020;12:1449. 10.3390/cancers12061449 PubMed DOI PMC

Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019;381:338-48. 10.1056/NEJMoa1817323 PubMed DOI

Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol 2020;38:1041-9. 10.1200/JCO.19.02044 PubMed DOI PMC

O'Donnell P, Galsky MD, Rosenberg JE, et al. 746P - EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors. Ann Oncol 2020;31:S579-S580. 10.1016/j.annonc.2020.08.818 DOI

Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021;384:1125-35. 10.1056/NEJMoa2035807 PubMed DOI PMC

Rosenberg JE, Flaig TW, Friedlander TW, et al. Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. J Clin Oncol 2020;38:abstr 441.

Hassler MR, Bray F, Catto JWF, et al. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. Eur Urol 2020;78:209-20. 10.1016/j.eururo.2020.05.039 PubMed DOI

Necchi A, Madison R, Pal SK, et al. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. Eur Urol Focus 2020. [Epub ahead of print]. doi: .10.1016/j.euf.2020.08.001 PubMed DOI

Yoshida T, Kates M, Fujita K, et al. Predictive biomarkers for drug response in bladder cancer. Int J Urol 2019;26:1044-53. 10.1111/iju.14082 PubMed DOI